Advanced Filters
noise

l'Hospitalet, Spain Clinical Trials

A listing of l'Hospitalet, Spain clinical trials actively recruiting patients volunteers.

Found 1,079 clinical trials
P Paloma Gastelurrutia

The Safety and Feasibility of the eLym™ System

The goal of this feasibility study is to evaluated the safety and performance of the WhiteSwell eLym System in the treatment of fluid overload or congestion in adult patients with Acute Decompensated Heart Failure (ADHF). The main question[s] it aims to answer are: Acute device safety (30 days) Chronic device …

18 years of age All Phase N/A
R Ricardo Frago, Ph D

Sarcopenia in Colorectal Cancer Patients, Intervention Study

The sarcopenia is a new concept for evaluating the functional status of patients, introduced during the last 20 years. This is defined as the relationship between the deterioration of muscle mass and the decrease in strength, the metabolic rate, the aerobic capacity and subsequently the evaluation of the functional status. …

70 years of age All Phase N/A
A Abi Temple

First in Human Study of T3P-Y058-739 (T3P)

This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.

18 - 74 years of age All Phase 1/2

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

The main purpose of this study is to determine the safety of different doses of OMX-0407. The study will also evaluate how the drug is distributed and exits the human body.

18 years of age All Phase 1/2
J Jorge Sanz Sanchez, MD, PhD

Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures

Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI). The decision whether to continue the DOAC throughout periprocedural period or interrupt DOAC before planned procedure represents a substantial …

years of age All Phase 4

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

18 years of age All Phase 1

Narrow Implants Vs Standard Implants With Simultaneous GBR

NDI represent an advisable treatment option when the mesio-distal space is compromised. In a recent retrospective study with a follow-up of 8 years in which they wanted to evaluate the long-term survival, complications, peri-implant conditions, marginal bone loss, and patient satisfaction of fixed dental prostheses supported by NDI in the …

18 - 80 years of age All Phase N/A

Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.

Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.

18 years of age All Phase 1
F Fritz Diekmann, MD, PhD

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group

A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.

19 - 76 years of age All Phase 3

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

30 - 74 years of age All Phase 1

Simplify language using AI